0.01
+92.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Prophase Labs
From its filings with the US Securities and Exchange Commission
Prophase Labs is based in New York, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker PRPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $4.3m and a net loss of $14.7m. At that date it held total assets of $59.9m and shareholders' equity of $3.5m.
We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.
We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. (“Nebula”) and DNA Complete, Inc. ("DNA Complete").
Our wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”) is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand.
Previously we offered a broad array of COVID-19 related clinical diagnostic and testing services including polymerase chain reaction (“PCR”) testing for COVID-19 and Influenza A and B as well as rapid antigen testing for COVID-19 through our wholly-owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”). ProPhase Diagnostics’ two CLIA (Clinical Laboratory Improvement Amendments) certified laboratories are located in Old Bridge, New Jersey and Garden City, New York, respectively.
Quoted from its 10-K, filed 1 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Jan 1984
- Employees
- 48
- Website
- prophaselabs.com ↗
- Head office
- 711 STEWART AVE, SUITE 200, NEW YORK, NY, 11530
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Ted KarkusChairman of the Board, Chief Executive Officer, since 2009$2.1m
- Mr. Steven PlumbFractional Chief Financial Officer
- Ms. Carolina AbenanteIndependent Director
- Dr. Louis GleckelIndependent Director$189,250
- Mr. Warren HirschIndependent Director$189,250
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ProPhase Labs develops OTC drugs and natural health products including TK Supplements and ORXx Complete.
- The company's products like LEGENDZ XL and TRIPLE EDGE XL target specific health segments such as male enhancement and energy.
- ProPhase Labs serves national wholesalers and pharmacies with its OTC healthcare offerings.
Weaknesses
- ProPhase Labs has only 48 employees, which may limit its operational capacity.
- The company's focus on OTC products restricts its market reach compared to broader pharmaceuticals.
- ProPhase Labs operates from New York City, which may increase operational costs.
Opportunities
- The growing OTC healthcare market presents opportunities for ProPhase Labs to expand its product line.
- Increasing demand for natural health products aligns with ProPhase Labs' focus on supplements and cosmeceuticals.
- ProPhase Labs can leverage its existing customer base of national wholesalers for new product launches.
Threats
- Competition from larger pharmaceutical companies could impact ProPhase Labs' market share.
- Regulatory changes in the OTC drug industry may require costly compliance adjustments.
- Economic downturns might reduce consumer spending on non-essential health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.